Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivarmacitinib Monotherapy in csDMARDs-IR Rheumatoid Arthritis
NCT07452445Phase 4Not yet recruiting
- Sponsor
- Tongji Hospital
- Start
- Mar 2026
- Primary completion
- Mar 2028
- Modality
- Small Molecules
01
Overview
Phase 4, open-label, single-arm trial of ivarmacitinib in rheumatoid arthritis (RA), sponsored by Tongji Hospital. Primary endpoint: American College of Rheumatology 20% improvement at 12 weeks. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
ivarmacitinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT07452445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07452445.